New York TimesBy GARDINER HARRISOctober 3, 2008
One of the nation’s most influential psychiatrists earned more than $2.8 million in consulting arrangements with drug makers from 2000 to 2007, failed to report at least $1.2 million of that income to his university and violated federal research rules, according to documents provided to Congressional investigators. The psychiatrist, Dr. Charles B. Nemeroff of Emory University, is the most prominent figure to date in a series of disclosures that is shaking the world of academic medicine and seems likely to force broad changes in the relationships between doctors and drug makers…
LA TimesBy Chad Terhune and Noam N. LeveSeptember 30, 2014Opening the book on long-hidden industry relationships, the federal government revealed nearly $3.5 billion worth of payments and other ties that U.S. doctors and teaching hospitals have with drug and medical-device companies. These financial details, published Tuesday under a requirement in the federal health law, have been sought for years by patient advocates and lawmakers from both political parties concerned about conflicts of interest in the medical profession.
Initially, the new federal website includes 4.4 million payments made during the last five months of 2013. More data will be published next summer. Officials said the data cover financial transactions involving about 546,000 physicians and 1,360 teaching hospitals across the country. Consumer advocates hope the increased disclosure will ultimately help curb unethical practices by some doctors who prescribe medications and devices after receiving large sums from manufacturers, possibly putting patient care at risk.
Physicians and academic medical centers defend industry collaboration as essential to advance research into life-saving treatments. They have also questioned the accuracy of the government data. The Physician Payments Sunshine Act was included in the Affordable Care Act that President Obama signed in 2010 amid growing demands for more openness in the U.S. healthcare system, which historically has shielded doctors, hospitals and other medical providers from much public scrutiny…
Those revelations of 2008 were the worst of times because I found out about the rampant corruption in the academic psychiatry pharmaceutical industry alliance. I had become a recluse after my own experiences and I felt guilty for not seeing what was happening in my own back yard. On the other hand, it was the best of times because it explained what had happened in my professional world that was so confusing, and it opened the door to trying to contribute to doing something about it. But looking back, 2008 was a confusing year, to say the least.
Harvard University
Edmond J. Safra Center for Ethicsby Paul ThackerFebruary 20, 2013…
It took more than five years to get it done.
Now that it’s all over, I can tell you it was worth it. This bill will bring some balance back to the relationship between doctors and industry. We need them to work together — industry needs the insight from expert physicians to create the next generation of drugs and devices, and doctors need these products to save lives. But we cannot tolerate companies buying off doctors who put profit before patients.
Years from now, I think people will look back on these reforms — the Grassley/Kohl Sunshine Act — and realize that they made academic medicine better. Few people will know about the staff behind the scenes making it possible. Even fewer will truly appreciate the long hours and great deal of stress we went through.
Even when Congress gets something done, it takes an incredibly long time and years of dedication.
Amen to that! Thanks.
Little rays of sunshine can do a whole lotta’ disinfecting.